Skip to main content
. Author manuscript; available in PMC: 2010 Feb 1.
Published in final edited form as: J Cardiovasc Pharmacol. 2009 Feb;53(2):121–131. doi: 10.1097/FJC.0b013e31819715c4

Figure 5.

Figure 5

Effects of BAY 41-2272 on VSM nuclear Cdk expression after 48 hours. A: Western blot showing Cdk-2 and Cdk-6 expression. B-C: Densitometry (normalized to α-tubulin) shows that BAY significantly and dose-dependently reduces expression of Cdk-2 (∼35%; p = 0.031) and Cdk-6 (∼60%; p < .001). Post-hoc results: *statistically significant with p < .05; **statistically significant with p < .01. Concomitant staining for APE/Ref1 verified nuclear localization of all samples (data not shown). Results are mean ± SEM, and n = 4 experiments/group.